Effect of Ulipristal Acetate for Uterine Fibroids

被引:0
|
作者
Deshpande, Preeti Suhas [1 ,2 ]
Deshpande, Suhas Suresh [1 ,2 ]
机构
[1] Ekopa Hosp, Dept Obstet & Gynaecol, Karad, Maharashtra, India
[2] Karad Fertil Res Ctr, Karad, Maharashtra, India
关键词
Fibroid; Ulipristal Acetate; Menorrhagia; Selective Progesterone Receptor Modulator; SPRM; MANAGEMENT; PLACEBO; SAFETY;
D O I
10.14260/jemds/2019/795
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Fibroids are the most common tumours of the female reproductive tract and have been reported to affect 20-40% of women during their reproductive years. Most fibroids are asymptomatic and require no treatment. We wanted to investigate the effectiveness of Ulipristal Acetate in reducing the fibroid volume, and giving symptomatic relief after 3 months treatment. METHODS This is a prospective interventional study conducted among 38 premenopausal women with symptomatic fibroids. They were evaluated clinically for the symptoms reported. Each underwent ultrasound before starting the treatment and after three months of Ulipristal treatment. Some patients had more than one fibroid and so in total the sizes of 56 fibroids were recorded. RESULTS After 3 months of ulipristal acetate treatment, patients had a significant improvement of all symptoms with fibroid volume reduction. CONCLUSIONS Fibroid treatment with ulipristal acetate resulted in a significant improvement of fibroid related symptoms and significant reduction in fibroid volume.
引用
收藏
页码:3675 / 3678
页数:4
相关论文
共 50 条
  • [12] Treatment of Symptomatic Uterine Fibroids with Ulipristal Acetate: Endometrial Safety
    Catherino, William
    Eisenhut, Carol
    Blakesley, Rick
    Chan, Anna
    Sniukiene, Vilma
    Goldstein, Steven
    MODERN PATHOLOGY, 2017, 30 : 279A - 279A
  • [13] The Clinical Pharmacology and Pharmacokinetics of Ulipristal Acetate for the Treatment of Uterine Fibroids
    Pohl, Oliver
    Zobrist, R. Howard
    Gotteland, Jean-Pierre
    REPRODUCTIVE SCIENCES, 2015, 22 (04) : 476 - 483
  • [14] Ulipristal acetate versus GnRH agonists in the treatment of uterine fibroids
    Ene, G.
    Albu, S.
    Stoian, R.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2015, 122 : 75 - 76
  • [15] THE RETINOIC ACID PATHWAY IN UTERINE FIBROIDS IS NOT AFFECTED BY ULIPRISTAL ACETATE
    Roura-Monllor, Jaime A.
    Britten, Joy
    Driggers, Paul
    Malik, Minnie
    Catherino, William H.
    FERTILITY AND STERILITY, 2023, 120 (04) : E316 - E316
  • [16] Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids
    Tafi, Emanuela
    Scala, Carolina
    Maggiore, Umberto Leone Roberti
    Bizzarri, Nicolo
    Candiani, Massimo
    Venturini, Pier Luigi
    Ferrero, Simone
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (06) : 965 - 977
  • [17] Allergan: FDA Accepts NDA for Ulipristal Acetate for Uterine Fibroids
    Fiorentino, Desiree G.
    OBSTETRICS AND GYNECOLOGY, 2018, 131 (01): : 161 - 162
  • [18] Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids
    Donnez, Jacques
    Hudecek, Robert
    Donnez, Olivier
    Matule, Dace
    Arhendt, Hans-Joachim
    Zatik, Janos
    Kasilovskiene, Zaneta
    Dumitrascu, Mihai Cristian
    Fernandez, Herve
    Barlow, David H.
    Bouchard, Philippe
    Fauser, Bart C. J. M.
    Bestel, Elke
    Terrill, Paul
    Osterloh, Ian
    Loumaye, Ernest
    FERTILITY AND STERILITY, 2015, 103 (02) : 519 - 527
  • [19] Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids
    Biglia, Nicoletta
    Carinelli, Silvestro
    Maiorana, Antonio
    D'Alonzo, Marta
    Lo Monte, Giuseppe
    Marci, Roberto
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2014, 8 : 285 - 292
  • [20] The Clinical Pharmacology and Pharmacokinetics of Ulipristal Acetate for the Treatment of Uterine Fibroids
    Oliver Pohl
    R. Howard Zobrist
    Jean-Pierre Gotteland
    Reproductive Sciences, 2015, 22 : 476 - 483